Shares of

Boston Scientific

(BSX) - Get Report

rose Monday following the announcement that the Food and Drug Administration had approved its product to reduce the risk of a heart attack following heart bypass surgery.

The Natick, Mass., company's stock gained 80 cents, or 2.3%, to $35.32. The company plans to launch the product in the U.S. immediately. The product, known as the Filter Wire EZ Embolic Protection System, has been available in Europe since September 2003.

The product is a revised version of a product first introduced in June 2003 for the treatment of saphenous vein graft (SVG) disease. Cardiac surgeons take a portion of this saphenous vein, found in the leg, and use it as the bypass vessel in the heart operation. But these veins can harden and clog over time, increasing the risk of a heart attack.

If the grafted saphenous vein becomes diseased, doctors must try to solve the problem by angioplasty, a procedure that clears obstructions from blood vessels. The Boston Scientific product is a filter used in this procedure; it collects materials dislodged during angioplasty. If these materials entered the blood stream, they could create a clot and cause a heart attack.